High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008

Autor: Whelan, J., Deley, M.C. le, Dirksen, U., Teuff, G. le, Brennan, B., Gaspar, N., Hawkins, D.S., Amler, S., Bauer, S., Bielack, S., Blay, J.Y., Burdach, S., Castex, M.P., Dilloo, D., Eggert, A., Gelderblom, H., Gentet, J.C., Hartmann, W., Hassenpflug, W.A., Hjorth, L., Jimenez, M., Klingebiel, T., Kontny, U., Kruseova, J., Ladenstein, R., Laurence, V., Lervat, C., Marec-Berard, P., Marreaud, S., Michon, J., Morland, B., Paulussen, M., Ranft, A., Reichardt, P., Berg, H. van den, Wheatley, K., Judson, I., Lewis, I., Craft, A., Juergens, H., Oberlin, O., Euro- E W I N G 99 Investigator, EWING-2008 Investigator

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 36(31), 3110
Journal of clinical oncology, 36(31), 3110-3119. American Society of Clinical Oncology

Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96eb6ac761dbaef5b72b0d7cac093a0c
https://doi.org/10.1200/jco.2018.78.2516

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Autor: Tsao, M.-S.^1,2 ming.tsao@uhn.ca, Teuff, G. Le^3,4, Shepherd, F. A.^5,6, Landais, C.³, Hainaut, P.⁷, Filipits, M.⁸, Pirker, R.⁸, Chevalier, T. Le⁹, Graziano, S.¹⁰, Kratze, R.¹¹, Soria, J.-C.⁹, Pignon, J.-P.^3,4, Seymour, L.¹², Brambilla, E.^7,13

Publikováno v: Annals of Oncology. Apr2017, Vol. 28 Issue 4, p882-889. 8p. 3 Charts, 2 Graphs.

7115 Prognostic value of cyclooxygenase-1 and cyclooxygenase-2 expressions in human renal cell carcinoma

Autor: Andreu, N., Meyer, F., Teuff, G. Le, Lacombe, L., Fradet, Y., Tetu, B.

Publikováno v: In EJC Supplements 2009 7(2):427-427

876PA new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation.

Autor: Derosa, L¹ (AUTHOR), Bayar, M A² (AUTHOR), Albiges, L¹ (AUTHOR), Teuff, G Le² (AUTHOR), Escudier, B¹ (AUTHOR)

Publikováno v: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.